TELO Telomir Pharmaceuticals, Inc. Common Stock
Healthcare$1.28+0.00%OpenMarket Cap: $44.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
8.94
P/S
0.00
EV/EBITDA
-4.18
DCF Value
$0.23
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-201.2%
ROA
-159.3%
ROIC
-189.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-1.0M | $-990.9K | $— | — |
| Q4 null | $0.00 | NaN% | $-2.1M | $-2.1M | $— | — |
| FY null | $0.00 | NaN% | $-10.5M | $-10.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.1M | $-1.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.1M | $-5.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.2M | $-2.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.9M | $-2.9M | $— | — |
| FY null | $0.00 | NaN% | $-12.2M | $-16.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-6.0M | $-6.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.5M | $-1.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.9M | $-6.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-1.1M | $-9.3M | $-0.32 | — |